论文部分内容阅读
目的探讨国产替考拉宁治疗革兰阳性球菌重症肺炎的临床疗效及安全性。方法将78例革兰阳性球菌重症肺炎患者分为观察组和对照组,观察组给予国产替考拉宁治疗,对照组行去甲万古霉素治疗,比较2组细菌清除率和临床疗效。结果观察组细菌清除率为87.0%,与对照组的86.0%对比无显著差异(P>0.05)。观察组平均清除时间为(12.5±2.2)d,短于对照组的(15.1±1.9)d(P<0.05)。观察组治疗总有效率90.0%,对照组为86.0%,二者对比差异无统计学意义(P>0.05)。观察组4例出现不良反应,不良反应发生率10.0%;对照组不良反应发生率13.0%,对比差异无统计学意义(P>0.05)。结论国产替考拉宁治疗革兰阳性球菌重度肺炎疗效确切,对常见痰菌清除率高,安全可靠,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of domestic teicoplanin in the treatment of Gram-positive cocci severe pneumonia. Methods Seventy-eight Gram-positive cocci pneumonia patients were divided into observation group and control group. The observation group was treated with domestic teicoplanin. The control group received norvancomycin treatment. The bacterial clearance rate and clinical efficacy of the two groups were compared. Results The bacterial clearance rate in the observation group was 87.0%, which was not significantly different from that in the control group (86.0%) (P> 0.05). The mean clearance time in the observation group was (12.5 ± 2.2) d, shorter than that in the control group (15.1 ± 1.9) d (P <0.05). The total effective rate was 90.0% in the observation group and 86.0% in the control group, with no significant difference between the two groups (P> 0.05). Adverse reactions were observed in 4 cases in observation group, the incidence of adverse reactions was 10.0%. The incidence of adverse reactions in control group was 13.0%. There was no significant difference between the two groups (P> 0.05). Conclusion Domestic teicoplanin for the treatment of Gram-positive cocci severe pneumonia curative effect is exact, common sputum bacteria clearance rate is high, safe and reliable, worthy of clinical application.